KR20020086911A - 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 - Google Patents
알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 Download PDFInfo
- Publication number
- KR20020086911A KR20020086911A KR1020027011063A KR20027011063A KR20020086911A KR 20020086911 A KR20020086911 A KR 20020086911A KR 1020027011063 A KR1020027011063 A KR 1020027011063A KR 20027011063 A KR20027011063 A KR 20027011063A KR 20020086911 A KR20020086911 A KR 20020086911A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- galantamine
- weeks
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims abstract description 128
- 229960003980 galantamine Drugs 0.000 title claims abstract description 63
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 238000004448 titration Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 208000017667 Chronic Disease Diseases 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- 230000006399 behavior Effects 0.000 description 16
- 230000008859 change Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 8
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 8
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010042772 syncope Diseases 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007074 memory dysfunction Effects 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- BLGKYYVFGMKTEZ-QVCIKPHISA-N D-galactosyl-N-hexadecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BLGKYYVFGMKTEZ-QVCIKPHISA-N 0.000 description 1
- SNPQGCDJHZAVOB-LUUMFRNDSA-N D-galactosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-LUUMFRNDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 241001502107 Galanthus alpinus Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101000887168 Gallus gallus Gallinacin-8 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 1
- 101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940006388 galantamine 8 mg Drugs 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- -1 pessaries Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| US60/194.259 | 2000-04-03 | ||
| PCT/EP2001/003553 WO2001074339A2 (fr) | 2000-04-03 | 2001-03-28 | Utilisation de la galantamine dans le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20020086911A true KR20020086911A (ko) | 2002-11-20 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027011063A Ceased KR20020086911A (ko) | 2000-04-03 | 2001-03-28 | 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (fr) |
| JP (1) | JP2003528913A (fr) |
| KR (1) | KR20020086911A (fr) |
| CN (1) | CN1430514A (fr) |
| AU (2) | AU6584401A (fr) |
| BG (1) | BG107093A (fr) |
| BR (1) | BR0109770A (fr) |
| CA (1) | CA2310926C (fr) |
| CZ (1) | CZ20023543A3 (fr) |
| EE (1) | EE200200554A (fr) |
| HR (1) | HRP20020778A2 (fr) |
| HU (1) | HUP0300566A3 (fr) |
| IL (1) | IL152061A0 (fr) |
| MX (1) | MXPA02009777A (fr) |
| NO (1) | NO20024746L (fr) |
| PL (1) | PL361272A1 (fr) |
| RU (1) | RU2002129298A (fr) |
| SK (1) | SK15422002A3 (fr) |
| WO (1) | WO2001074339A2 (fr) |
| ZA (1) | ZA200207935B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ATE374030T1 (de) * | 2003-07-25 | 2007-10-15 | Hoffmann La Roche | Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| DK2271218T3 (en) | 2008-03-27 | 2017-09-11 | Chase Pharmaceuticals Corp | USE AND COMPOSITION TO TREAT DEMENS |
| WO2013160728A1 (fr) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Composés à double ciblage pour le traitement de la maladie d'alzheimer |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (fr) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | Clairance de galantamine d'amyloides |
| WO2023036105A1 (fr) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | Méthode de traitement d'une maladie neurodégénérative |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| EP1133230A4 (fr) | 1998-11-23 | 2004-05-26 | Bonnie M Davis | Formulations de dosage d'inhibiteurs de l'acetylcholinesterase |
| ID29021A (id) * | 1998-12-24 | 2001-07-26 | Janssen Pharmaceutica Nv | Komposisi galantamina pelepasan terkontrol |
| CA2310950C (fr) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | Posologie de galantamine efficace qui reduit les effets secondaires |
| CA2310990A1 (fr) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/fr not_active Expired - Lifetime
-
2001
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 EP EP01943200A patent/EP1272192A2/fr not_active Withdrawn
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/fr not_active Ceased
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Ceased
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0300566A2 (hu) | 2003-06-28 |
| BR0109770A (pt) | 2003-02-04 |
| EE200200554A (et) | 2004-04-15 |
| BG107093A (bg) | 2003-06-30 |
| NO20024746D0 (no) | 2002-10-02 |
| CN1430514A (zh) | 2003-07-16 |
| AU6584401A (en) | 2001-10-15 |
| HUP0300566A3 (en) | 2004-10-28 |
| MXPA02009777A (es) | 2003-03-27 |
| ZA200207935B (en) | 2004-01-30 |
| SK15422002A3 (sk) | 2003-04-01 |
| CA2310926C (fr) | 2002-10-15 |
| EP1272192A2 (fr) | 2003-01-08 |
| NO20024746L (no) | 2002-11-28 |
| HRP20020778A2 (en) | 2004-04-30 |
| WO2001074339A2 (fr) | 2001-10-11 |
| CA2310926A1 (fr) | 2000-10-04 |
| CZ20023543A3 (cs) | 2003-03-12 |
| JP2003528913A (ja) | 2003-09-30 |
| PL361272A1 (en) | 2004-10-04 |
| IL152061A0 (en) | 2003-05-29 |
| AU2001265844B2 (en) | 2005-04-14 |
| WO2001074339A3 (fr) | 2002-09-12 |
| RU2002129298A (ru) | 2004-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuna et al. | Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study | |
| Amass et al. | Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet | |
| Biastre et al. | Trospium chloride treatment of overactive bladder | |
| TW202110450A (zh) | 使用布魯頓酪胺酸激酶抑制劑治療慢性自發性蕁麻疹之方法 | |
| US20120010242A1 (en) | Low dose pipamperone in treating mood disorders | |
| CA2310950C (fr) | Posologie de galantamine efficace qui reduit les effets secondaires | |
| Casey et al. | Sulpiride in tardive dyskinesia | |
| KR20020086911A (ko) | 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 | |
| JPH0920666A (ja) | 成熟遅延および類似疾患の治療用医薬組成物 | |
| JPH0667842B2 (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| Amore et al. | Long-term treatment of geropsychiatric depressed patients with venlafaxine | |
| CN109069466A (zh) | 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 | |
| AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| US20040067934A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| Van Bijsterveld et al. | Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate A double-masked placebo controlled group comparative study | |
| Bullock et al. | Risperidone in the treatment of psychoses in the elderly: a case report series | |
| Sheehan et al. | Adinazolam sustained release formulation in the treatment of generalized anxiety disorder | |
| US20240358693A1 (en) | Methods of treating pain | |
| Bennie et al. | Comparison of trazodone and mianserin in depressive illness | |
| Gerlach | Pharmacology and clinical properties of selective dopamine antagonists with focus on substituted benzamides | |
| Wheatley | Ginkgo biloba relieves sexual dysfunction due to antidepressant drugs | |
| TW202428261A (zh) | 用於治療重症肌無力的組成物與方法 | |
| Pitt et al. | A Review of the Use of Donepezil in the Treatment of Alzheimer’s Disease | |
| Panas et al. | Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review | |
| EP4615577A1 (fr) | Méthodes de traitement de douleurs et de troubles oculaires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20020823 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20060327 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070322 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20070731 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20070322 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |